Basiglar and Semglee Dosing: Identical Biosimilar Formulations
Basiglar and Semglee are both biosimilar formulations of insulin glargine 100 units/mL and should be dosed identically to the reference product Lantus, with no dosing differences between them.
Initial Dosing for Type 2 Diabetes
For insulin-naive patients with type 2 diabetes, start with 10 units once daily OR 0.1-0.2 units/kg body weight, administered at the same time each day 1, 2. Continue metformin unless contraindicated, and possibly one additional non-insulin agent 1, 2.
Severe Hyperglycemia Requires Higher Starting Doses
For patients with blood glucose ≥300-350 mg/dL and/or A1C ≥10-12% with symptomatic or catabolic features, consider starting with basal-bolus insulin immediately rather than basal insulin alone, using 0.3-0.5 units/kg/day as total daily insulin dose 1.
For marked hyperglycemia with A1C ≥9% but not requiring immediate basal-bolus therapy, consider more aggressive starting doses of 0.3-0.4 units/kg/day to achieve glycemic targets faster 1.
Titration Algorithm
Increase the dose by 2-4 units (or 10-15%) once or twice weekly until fasting blood glucose reaches 80-130 mg/dL 3, 1, 2. The specific increment depends on current glucose levels:
- If fasting glucose ≥180 mg/dL: increase by 4 units every 3 days 1
- If fasting glucose 140-179 mg/dL: increase by 2 units every 3 days 1
- If hypoglycemia occurs: reduce dose by 10-20% immediately 1
Equip patients with self-titration algorithms based on self-monitoring of blood glucose, as this approach improves glycemic control 3, 1.
Initial Dosing for Type 1 Diabetes
For type 1 diabetes, start with a total daily insulin dose of 0.5 units/kg/day, giving approximately 50% as basal insulin (Basiglar/Semglee) once daily and 50% as prandial insulin divided among meals 1, 2.
Metabolically stable patients typically require 0.5 units/kg/day, while total daily requirements can range from 0.4-1.0 units/kg/day 1, 2. Higher doses are needed during puberty, pregnancy, and medical illness 1.
Critical Threshold: When to Stop Escalating Basal Insulin
When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, add prandial insulin rather than continuing to escalate basal insulin alone 1, 2. This prevents "overbasalization," which causes hypoglycemia and suboptimal control 1.
Clinical Signals of Overbasalization
Watch for these warning signs 1:
- Basal dose >0.5 units/kg/day
- Bedtime-to-morning glucose differential ≥50 mg/dL
- Hypoglycemia episodes
- High glucose variability
Adding Prandial Insulin
When basal insulin has been optimized (fasting glucose 80-130 mg/dL) but A1C remains above target after 3-6 months, start with 4 units of rapid-acting insulin before the largest meal OR use 10% of the current basal dose 1, 2. Titrate prandial insulin by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings 1.
Monitoring Requirements
Daily fasting blood glucose monitoring is essential during titration 1, 2. Assess adequacy of insulin dose at every clinical visit, looking specifically for signs of overbasalization 1.
Common Pitfalls to Avoid
- Never delay insulin initiation in patients not achieving glycemic goals with oral medications, as this prolongs hyperglycemia exposure and increases complication risk 1
- Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain 1
- Never continue escalating basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to overbasalization with increased hypoglycemia risk 1
Administration Considerations
Both Basiglar and Semglee are typically administered once daily at bedtime, but can be given in the morning or at any other time convenient for the patient 4. In labile type 1 diabetes or obese insulin-resistant patients requiring high volumes, twice-daily dosing may be more effective 4.
Do not mix Basiglar or Semglee with any other insulin or solution due to its low pH 1. This requires separate injections when combining basal and prandial insulin 1.